New York, May 27, 2026, 16:06 (EDT)
- XTLB last traded at $2.44, rising roughly 2.5% from where it ended before. The stock moved between $2.381 and $2.590 during the session.
- The company earlier said it planned to ask for an extended stay of any Nasdaq suspension by May 26.
- Nasdaq wrapped up its regular session, which runs from 9:30 a.m. to 4 p.m. ET. After-hours go until 8 p.m. ET, according to the exchange.
XTL Biopharmaceuticals Ltd. shares ticked up Wednesday, with traders focused on the Nasdaq hearing process that may determine if the Israeli biotech will retain its U.S. listing.
The stock traded at $2.44, rising 2.5% from its last close at $2.38. Nasdaq Composite barely changed, up 0.07%. S&P 500 edged up 0.02%. The company’s listing dispute was the driver, not the broad market.
XTL said last week it faces a May 26 deadline to explain to the Nasdaq Hearings Panel why its latest filing miss should not strengthen the argument for delisting and to request another stay on suspension. If XTL asks for the stay, the panel is set to respond with its decision within 15 calendar days of the deadline.
Nasdaq raised a new concern over XTL after the company missed its 2025 Form 20-F filing. That’s the annual report foreign firms have to send the U.S. Securities and Exchange Commission. XTL was already facing a panel review for breaking Nasdaq’s $2.5 million minimum equity rule—meaning equity after debts—and the $1 bid price rule, which is Nasdaq’s lowest allowed price for a listed stock.
XTL, which has a market cap near $6.0 million, needs the Nasdaq listing to move forward. The firm is working on a Psyga Bio deal and financing plan that are both linked to keeping its spot on the exchange. According to its proxy, Nasdaq’s panel will let XTL stay listed if it can close the deal and meet listing requirements by June 30.
Investors will vote June 22 on a plan to buy 80% to all of Psyga Bio. The ballot also covers a private placement for as much as $1.5 million and a large jump in authorized share capital. Authorized shares are what a company can issue; increasing them lets a company raise cash but can dilute current holders.
XTL is looking to push further into psychedelic and functional mushroom-based drugs with the Psyga deal. Psyga’s founder and scientific leader, Professor Dedi Meiri, said the firm has built “a true pharmaceutical infrastructure.” In its April release, XTL said the purchase would add clinical assets and GMP manufacturing to the public company. GlobeNewswire
XTL is now close to an active area of biotech. Compass Pathways back in February reported that its second Phase 3 trial with COMP360 psilocybin for treatment-resistant depression hit the main goal. AtaiBeckley shows it has Phase 2 trials under way in the same area.
The policy environment has been a boost. Reuters said in April the U.S. Food and Drug Administration sped up its review of some psychedelic drugs after an executive order. Compass said it got a priority voucher for COMP360. Michael Thase, psychiatry professor at University of Pennsylvania, told Reuters psilocybin has drawn most of the attention because its clinical profile is further along.
The risks are clear. If the panel does not continue the stay or if XTL does not meet requirements, its ADSs—American depositary shares of its foreign stock—could get suspended from Nasdaq. XTL’s proxy warns that a Nasdaq delisting could force a rethink of the Psyga deal terms. If new ADSs and warrants are issued for the planned share-capital increase, that could mean dilution for holders.
Panel action on the stay, the missing annual filing, and the June 22 shareholder vote are the next things to watch. Until something breaks on one of those, XTLB keeps trading like a listing risk, not a healthcare development play.
